Shelter Pharma Board of Directors
Get the latest insights into the leadership at Shelter Pharma. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Mustaqim Nisarahmed Sabugar | Managing Director |
| Mr. Shakil Nisarahmed Sabugar | Whole Time Director |
| Ms. Parvezbanu Mohamed Rafiq Idariya | Non Executive Director |
| Mr. Mosinkhan Gafarkhan Pathan | Independent Director |
| Mr. Riyajahmed Abdulrauf Sabugar | Independent Director |
Shelter Pharma Share price
SHELTER
44.51
0.71 (-1.57%)Last updated on 4 Sep, 2025 | 15:18 IST
BUYSELL
Today's High
46.98
Today's Low
44.51
52 Week Low
35.70
52 Week High
69.70
The current prices are delayed, login to your account for live prices
LoginShelter Pharma FAQs
The board at Shelter Pharma consists of experienced professionals, including Mr. Mustaqim Nisarahmed Sabugar , Mr. Shakil Nisarahmed Sabugar , and others, overseeing the company’s strategic and corporate governance.
Directors at Shelter Pharma are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Mustaqim Nisarahmed Sabugar is the current chairman at Shelter Pharma.
Executive directors at Shelter Pharma are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Shelter Pharma adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Shelter Pharma, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.